Skip to content

Effect of Livogrit on Quality of Life in Patients with Non-Alcoholic Fatty Liver Disease

Evaluation of the Impact of Ayurvedic Formulation Livogrit on Quality of Life in Patients with Non-Alcoholic Fatty Liver Disease Prospective open label single arm observational study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/06/089641
Enrollment
91
Registered
2025-06-26
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: Nil: Nil

Sponsors

Patanjali Research Foundation
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Established case of NAFLD (Grade I & II). The subject is able and willing to provide consent.

Exclusion criteria

Exclusion criteria: Alcohol associated liver disease (ALD) engage in heavy drinking about 4 or more drinks per day (56g) or 8 (112 g) or more drinks per week for women and 5 or more drinks per day (70 g) or 15 (210 g) or more drinks per week for men and other causes of liver disease. Any dysfunction of liver besides non-alcoholic fatty liver disease like viral hepatitis liver parenchymal disease, ascites, portal hypertension, Hepato-cellular carcinoma, Auto- immune hepatitis, Primary biliary cirrhosis, Wilsons disease, and liver transplantation. Inability to attend follow-up session. Pregnant, lactating women or pregnancy anticipated during study. Diagnosed cases of Diabetes. Thyroid disease not controlled by medication. Uncontrolled Hypertension. Patient on Anti-tubercular therapy. Known cases of endocrine disorders including Cushing s syndrome or history of long term steroid intake or any other secondary causes of fatty liver. Patients with complications of Metabolic syndrome like Cerebrovascular Accident Myocardial Infarction Chronic Kidney disease. Patient not willing to give written informed consent.

Design outcomes

Primary

MeasureTime frame
Changes in the Chronic Liver Disease Questionnaire for NAFLD NASHTimepoint: baseline (Day 1) to Day 90

Secondary

MeasureTime frame
Changes in Liver Function Test (LFT)Timepoint: baseline (Day 1) to Day 90

Countries

India

Contacts

Public ContactDr Kumud Chauhan

Patanjali Yoggram Yog Naturopathy Panchkarma Treatment and Research Centre

kumudchauhan3@gmail.com07456938311

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026